OPIANT PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Jul 31, 2017
Cash flows provided by (used in) operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Amortization of debt discount
Operating leases amortization
Issuance of common stock for services
Stock based compensation from issuance of options
Stock based compensation from issuance of warrants
Note payable issued for services
Stock based compensation expense
(Gain) loss on settlement of debt
Changes in assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable and accrued liabilities
License fees payable
Accrued salaries and wages
Decrease in operating lease liabilities
Operating lease liabilities
Royalty payable
Deferred revenue

Net cash provided by (used in) operating activities
Cash flows used in investing activities
Purchase of marketable securities
Purchase of property and equipment
Net cash used in investing activities
Proceeds from related parties notes payable
Repayment of related parties notes payable
Cash flows provided by financing activities
Proceeds from debt issuance
Debt issuance costs
Proceeds from exercise of options and warrants
Payment of financing costs
Proceeds from sale of common stock
Repayment of note payable
Investment received in exchange for royalty agreement
Net cash provided by financing activities

Net increase in cash and cash equivalents
Effect of foreign currency translation on cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosure
Interest paid during the period
Interest paid during the year
Taxes paid during the year

Non-Cash Investing and Financing Transactions
Forgiveness of related party debt
Cashless exercise of options
Issuance of common stock to net profit partner
Issuance of restricted stock
Forgiveness of related party of debt
Common stock issued for debt conversion
Debt issuance cost associated with debt conversion
Right of use assets obtained in exchange for new lease obligations
Offset of deferred financing costs against APIC

Comments